1.Jie, Z.; Xia, H.; Zhong, S.L.; Feng, Q.; Li, S.; Liang, S.; Zhong, H.; Liu, Z.; Gao, Y.; Zhao, H.; et al. The gut microbiome in atherosclerotic cardiovascular disease.Nat. Commun.2017,8, 845, doi:10.1038/s41467-01700900-1.;2.Jousimies-Somer, H.R. & Summanen, Paula & Citron, D.M. & Baron, Ellen & Wexler, Hannah & Finegold, Sydney. (2002). Wadsworth-KTL Anaerobic Bacteriology Manual3.Karlsen, S., Fynne, L., Grønbæk, H., & Krogh, K. Small intestinal transit in patients with liver cirrhosis and portal hypertension: a descriptive study //BMC gastroenterology. –2012. –V. 12. –No. 1. –P. 176-180.4.Karlsson, F.H.; Fåk, F.; Nookaew, I.; Tremaroli, V.; Fagerberg, B.; Petranovic, D.; Bäckhed, F.; Nielsen, J. Symptomatic atherosclerosis is associated with an Lee S. Y., Soltesz I. Cholecystokinin: A multi‐functionalmolecular switch of neuronal circuits //Developmentalneurobiology. –2011. –V. 71. –No. 1. –P. 85-87.; 5.LeLeiko R. M., Vaccari C. S., Sola S., Merchant N., Nagamia S. H., Thoenes M., Khan B. V. Usefulness of elevations in serum choline and free F2)-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome // Am J Cardiol. ‒ 2009. ‒ Vol. 104, No 5. ‒ P. 638-643.6.Lewis G. D., Wei R., Liu E., Yang E., Shi X., Martinovic M., Farrell L., Asnani A., Cyrille M., Ramanathan A., Shaham O., Berriz G., Lowry P. A., Palacios I. F., Tasan M., Roth F. P., Min J., BaumgartnerC., Keshishian H., Addona T., Mootha V. K., Rosenzweig A., Carr S. A., Fifer M. A., Sabatine M. S., Gerszten R. E. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury // J ClinInvest. ‒ 2008. ‒ Vol. 118, No 10. ‒ P. 3503-3512